Rapid health technology assessment of Aidi injection combined with first-line chemotherapy for non-small cell lung cancer
- VernacularTitle:艾迪注射液联合一线化疗用于NSCLC的快速卫生技术评估
- Author:
Congcong XU
1
;
Liulü HUANG
1
;
Jiao TANG
1
;
Ying LIU
1
;
Yonglong HAN
1
Author Information
1. Dept. of Pharmacy，Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine，Shanghai 201306，China
- Publication Type:Journal Article
- Keywords:
Aidi injection;
chemotherapy;
non-small cell lung cancer;
rapid health technology assessment;
pharmacoeconomic
- From:
China Pharmacy
2023;34(10):1247-1251
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the effectiveness， safety and economics of Aidi injection combined with first-line chemotherapy for non-small cell lung cancer （NSCLC）， and to provide evidence-based reference for clinical drug use and decision. METHODS Retrieved from PubMed， Embase， the Cochrane Library， CNKI， Wanfang databases， VIP and Health Technology Assessment （HTA） related websites， HTA reports， systematic evaluation/meta-analysis and economic evaluations about Aidi injection combined with first-line chemotherapy for NSCLC were collected from the inception to Aug. 2022. After data extraction and quality evaluation， descriptive analysis was performed for the results of included studies. RESULTS A total of 16 pieces of literature were included， involving 1 piece of systematic review， 13 pieces of meta-analysis， 2 pieces of pharmacoeconomic studies. Compared with first-line chemotherapy， Aidi injection combined with first-line chemotherapy could improve response rate and disease control rate， prolonged survival time， improved survival quality， reduced the incidence of nausea and vomiting， leukocytopenia and thrombocytopenia， and improved immune function， but had controversial effects on liver and kidney function. With the payment threshold set by 3 times the national per capita GDP in 2019， Aidi injection combined with first-line chemotherapy had a more economical probability. CONCLUSIONS Aidi injection combined with first-line chemotherapy for NSCLC has good efficacy and safety， and has certain economic benefits. However， given the limited pharmacoeconomic studies included， the economic conclusions obtained need to be carefully interpreted.
